Gyrolab platforms automate nanoliter-scale immunoassays to accelerate assay development and bioanalysis for time critical workflows throughout biopharma development – from preclinical R&D, through bioprocess development and into regulated clinical trials. The affinity flow-through format eliminates incubations and shortens run times. Rapid parallel processing with precision means that Gyros’ technology ensures high reproducibility and productivity, with up to 112 data points generated per CD in under an hour. Gyros’ technology helps your team develop assays in less time than manual methods and increase throughput – quickly, efficiently and reliably.
What will you learn?
- The value of scaling down immunoassays to a nanoliter format
- The high throughput that can be achieved with walk-away automation
- The versatility of Gyros’ technology throughout biopharma development
Robert Durham, PhD, is currently the Director of Field Application Scientists for Gyros, Inc. in North America. In this role his responsibilities include: managing a team of field application scientists; training and support of new assay development; and qualification and validation on the Gyrolab™ platform. He brings to this position extensive expertise in the development and validation of immunoassays to support translational medicine projects in drug development for neuroscience and pharmacology. Robert received an MS in Biology in 1993 and a PhD in Pharmacology and Neurosciences in 1997 from Michigan State University. He completed a post-doctoral fellowship at Parke-Davis Pharmaceutical Research in 2000, where he evaluated and characterized animal models of Alzheimer’s disease.
For a full list of other webinars available on Bioanalysis Zone please see here.